Liver diseases constitute a major global health challenge, accounting for approximately two million deaths annually, with etiologies ranging from viral hepatitis and alcohol abuse to drug-induced hepatotoxicity. The limitations of conventional hepatoprotective therapies, including high costs and adverse effects, have necessitated the exploration of medicinal plants as alternative therapeutic agents. Euphorbia hirta has a long history of traditional use in the management of hepatic disorders; however, its therapeutic potential against chemically-induced liver damage requires scientific validation. This study was therefore designed to investigate the ameliorative effect of the aqueous leaf extract of E. hirta on carbon tetrachloride (CCl₄)-induced hepatotoxicity in albino Rats, alongside its phytochemical composition and acute toxicity profile. Thirty-six (36) Wistar albino rats were randomly divided into five groups. Hepatotoxicity was induced by intraperitoneal administration of CCl₄ (1:1 in olive oil, 1 mL/kg). Group I served as the normal control (received normal saline), while Group II served as the disease control (received CCl₄ only). Groups III, IV, and V received daily oral treatment with the standard drug (Silymarin, 100 mg/kg), low-dose E. hirta extract (100 mg/kg), and high-dose E. hirta extract (300 mg/kg), respectively. Serum levels of liver function biomarkers: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), and Total Bilirubin—were assessed, and liver tissues were examined histopathologically. Acute toxicity (LD₅₀) was determined following OECD guidelines, and preliminary phytochemical screening was conducted using standard protocols. The acute toxicity test revealed that the aqueous leaf extract of E. hirta was safe, with no mortality observed at a dose of 5000 mg/kg, indicating an LD₅₀ greater than 5000 mg/kg. Induction of liver damage significantly (P<0.05) increased serum AST, ALT, ALP and serum total bilirubin while administration of the standard drug and E. hirta to rats significantly (p<0.05) reduced it. Dose and time dependent responses were found in the normalization of the liver function indices. Histopathological examination further corroborated the biochemical findings; livers of CCl₄-treated rats exhibited severe hepatocellular necrosis, fatty infiltration, and inflammatory cell aggregation, whereas treatment with E. hirta extract markedly attenuated these lesions, with the high dose demonstrating near-normal hepatic architecture. In conclusion, the overall results showed that aqueous leaf extract of Euphorbia hirta has phytochemical components that can be used in treating liver damages.